Similar improvements in hip bone mineral density with monthly oral ibandronate (150mg) versus weekly oral alendronate (70mg) in postmenopausal osteoporosis

被引：0
|
作者：
Borges, J. L. C. [1 ]
Bolognese, M. [2 ]
Epstein, S. [3 ]
Sedarati, F. [4 ]
Neate, C. [5 ]
Miller, P. D. [6 ]
机构：
[1] Univ Catolica Brasilia, Brasilia, DF, Brazil
[2] Bethesda Hlth Res, Bethesda, MD USA
[3] New York & Doylestown Hosp, Mt Sinai Sch Med, Doylestown, PA USA
[4] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[5] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[6] Colorado Ctr Bone Res, Lakewood, CO USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
T377
引用
收藏
页码：S326 / S326
页数：1
相关论文
共 50 条
  • [1] Clinical comparison in BMD gains with monthly oral ibandronate (150mg) and weekly oral alendronate (70mg): Results from the MOTION study
    Miller, P. D.
    Zerbini, C. A. F.
    Recker, R. R.
    Sedarati, F.
    Neate, C.
    Reginster, J. Y.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S451 - S451
  • [2] Similar bone mineral density gain for oral monthly ibandronate and weekly alendronate in postmenopausal osteoporosis
    Sunyecz, John
    Cosman, Felicia
    Miller, Paul
    Kohles, Joseph D.
    Dasic, Gorana
    Recker, Robert
    [J]. OBSTETRICS AND GYNECOLOGY, 2008, 111 (04): : 10S - 10S
  • [3] Efficacy and Tolerability of Once-Monthly Oral Ibandronate (150 mg) and Once-Weekly Oral Alendronate (70 mg): Additional Results From the Monthly Oral Therapy With Ibandronate for Osteoporosis Intervention (MOTION) Study
    Emkey, Ronald
    Delmas, Pierre D.
    Bolognese, Michael
    Borges, Lindolfo C.
    Cosman, Felicia
    Ragi-Eis, Sergio
    Recknor, Christopher
    Zerbini, Cristiano A.
    Neate, Colin
    Sedarati, Farhad
    Epstein, Solomon
    [J]. CLINICAL THERAPEUTICS, 2009, 31 (04) : 751 - 761
  • [4] Once-monthly oral ibandronate versus weekly oral alendronate in postmenopausal osteoporosis: Rationale and design of motion
    Epstein, S.
    Borges, J. L. C.
    Mautalen, C.
    Gonzalez Macias, J.
    Mahoney, P.
    El Azzouzi, B.
    Masanauskaite, D.
    Cosman, F.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S252 - S252
  • [5] A single zoledronic acid 5mg infusion is preferred over weekly 70mg oral alendronate in a clinical trial of postmenopausal women with osteoporosis/osteopenia
    Lindsay, R.
    Saag, K.
    Kriegman, A.
    Davis, J.
    Beamer, E.
    Zhou, W.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S240 - S240
  • [6] A single zoledronic acid 5mg infusion is preferred over weekly 70mg oral alendronate in a clinical trial of postmenopausal women with osteoporosis/ osteopenia
    Lindsay, R.
    Saag, K.
    Kriegman, A.
    Davis, J.
    Beamer, E.
    Zhou, W.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S43 - S44
  • [7] Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg
    Epstein, S.
    Jeglitsch, M.
    McCloskey, E.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2951 - 2960
  • [8] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
    Hadji, P.
    Benhamou, C. -L.
    Devas, V.
    Masanauskaite, D.
    Barrett-Connor, E.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69
  • [9] The BALTO II study: Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis
    Minne, H.
    Bourgeois, P.
    Devas, V.
    Masanauskaite, D.
    Minic, B.
    Licata, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 423 - 423
  • [10] Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: The BALTO II study
    不详
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S127 - S128
12345